摘要
胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)由肠道内分泌细胞产生。GLP-1受体激动剂(GLP-1 receptor agonists,GLP-1RAs)促进葡萄糖相关的胰岛素分泌和抑制胰高血糖素分泌。GLP-1RAs还能抑制胃排空、食物摄入和限制体质量增加。在过去的十年中,GLP-1RAs对心血管系统影响的研究已经取得重大进展。口服小分子GLP-1RAs具有潜在优势,可以提高该类药物的应用。该文综述了GLP-1RAs在心血管疾病治疗中的多种作用,为GLP-1RAs的心血管获益提供新见解。
Glucagon-like peptide-1(GLP-1)is secreted by gut enteroendocrine cells.GLP-1 receptor agonists(GLP-1RAs)control glucose-related augmentation of insulin and suppress glucagon secretion.GLP-1RAs also inhibit gastric emptying,food intake and limit weight gain.In the past decade,significant progresses have been made in the investigation on the effects of GLP-1RAs on cardiovascular system.The potential advantages of oral small-molecule GLP-1RAs could improve the application of this class of drugs.This review highlights the multiple cardiovascular profiles of GLP-1RAs in the treatment of cardiovascular diseases to provide new insights into cardiovascular benefits of GLP-1RAs.
作者
柯志强
马倩倩
李丹
赵辛元
刘超
苏正定
KE Zhi-qiang;MA Qian-qian;LI Dan;ZHAO Xin-yuan;LIU Chao;SU Zheng-ding(Hubei Key Laboratory of Diabetes and Angiopathy,Xianning Medical College,Hubei University of Science and Technology,Xianning Hubei 437100,China;Cooperative Innovation Center of Industrial Fermentation(Ministry of Education&Hubei Province),Hubei University of Technology,Wuhan 430068,China;Department of Neonatology,Xianning Central hospital/First Affiliated Hospital of Hubei University of Science and Technology,Xianning Hubei 437100,China;National Demonstration Center for Experimental General Medicine Education,Xianning Medical College,Hubei University of Science and Technology,Xianning Hubei 437100,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2024年第3期426-430,共5页
Chinese Pharmacological Bulletin
基金
湖北省教育厅科学研究计划指导性项目(NoB2021224)
湖北省中医药管理局中医药科研项目(NoZY2023F149)。
